| DNA replication |
2.05 |
0.00e+0 |
34/36 (94.44%) |
DNA2;POLE2;RFC5;...
|
| Drug metabolism |
1.97 |
2.99e-3 |
78/151 (51.66%) |
ADH5;GSTA1;CES2;...
|
| Retinol metabolism |
1.89 |
3.99e-3 |
41/68 (60.29%) |
ALDH1A3;ADH5;RDH11;...
|
| Fanconi anemia pathway |
1.78 |
3.89e-2 |
36/54 (66.67%) |
RMI1;RAD51C;FANCA;...
|
| Glutathione metabolism |
1.73 |
4.66e-2 |
43/57 (75.44%) |
GSTA1;GSTP1;GPX3;...
|
| Non-homologous end-joining |
1.72 |
4.48e-2 |
11/13 (84.62%) |
FEN1;PRKDC;MRE11;...
|
| Oxidative phosphorylation |
1.70 |
4.01e-2 |
93/133 (69.92%) |
NDUFB1;NDUFA3;COX6B1;...
|
| Pantothenate and CoA biosynthesis |
1.67 |
4.71e-2 |
14/21 (66.67%) |
DPYD;ALDH3A2;ENPP1;...
|
| Propanoate metabolism |
-1.68 |
2.30e-2 |
30/34 (88.24%) |
ACAT2;BCKDHA;LDHA;...
|
| Yersinia infection |
-1.69 |
2.24e-2 |
120/137 (87.59%) |
DOCK1;LCP2;MEFV;...
|
| Chagas disease |
-1.69 |
2.31e-2 |
93/102 (91.18%) |
GNAO1;PLCB4;FASLG;...
|
| T cell receptor signaling pathway |
-1.70 |
2.30e-2 |
93/104 (89.42%) |
MAPK1;MAP3K8;DLG1;...
|
| Mineral absorption |
-1.71 |
2.13e-2 |
48/60 (80%) |
SLC39A4;MT1F;TRPV6;...
|
| MicroRNAs in cancer |
-1.71 |
2.21e-2 |
146/310 (47.1%) |
MAPK1;CRKL;SOX4;...
|
| PD-L1 expression and PD-1 checkpoint pathway in cancer |
-1.71 |
2.13e-2 |
79/89 (88.76%) |
MAPK1;MAPK11;TLR2;...
|
| Non-small cell lung cancer |
-1.72 |
2.21e-2 |
70/72 (97.22%) |
HGF;FOXO3;CASP9;...
|
| Glyoxylate and dicarboxylate metabolism |
-1.72 |
2.19e-2 |
23/30 (76.67%) |
CS;ACAT2;GRHPR;...
|
| Malaria |
-1.73 |
2.22e-2 |
44/50 (88%) |
SELP;TLR2;ICAM1;...
|
| PI3K-Akt signaling pathway |
-1.74 |
2.16e-2 |
317/354 (89.55%) |
FASLG;CDC37;TNC;...
|
| Shigellosis |
-1.74 |
2.27e-2 |
180/246 (73.17%) |
CDC42;CSF2;PIK3R4;...
|
| HIF-1 signaling pathway |
-1.77 |
1.97e-2 |
105/109 (96.33%) |
SLC2A1;NPPA;MAPK1;...
|
| Pancreatic cancer |
-1.77 |
2.09e-2 |
75/76 (98.68%) |
CASP9;MAPK1;RALB;...
|
| Central carbon metabolism in cancer |
-1.77 |
2.04e-2 |
67/70 (95.71%) |
SLC2A1;SCO2;TIGAR;...
|
| AGE-RAGE signaling pathway in diabetic complications |
-1.78 |
1.80e-2 |
97/100 (97%) |
CDC42;SERPINE1;THBD;...
|
| Adherens junction |
-1.79 |
1.52e-2 |
63/71 (88.73%) |
CSNK2B;PARD3;TGFBR2;...
|
| Endometrial cancer |
-1.81 |
1.31e-2 |
56/58 (96.55%) |
FOXO3;CASP9;MAPK1;...
|
| Melanoma |
-1.81 |
1.42e-2 |
68/72 (94.44%) |
FGF9;HGF;FGF1;...
|
| Bladder cancer |
-1.82 |
1.16e-2 |
40/41 (97.56%) |
MAPK1;DAPK1;FGFR3;...
|
| Aldosterone-regulated sodium reabsorption |
-1.83 |
8.51e-3 |
34/37 (91.89%) |
NEDD4L;MAPK1;PIK3CA;...
|
| Bacterial invasion of epithelial cells |
-1.84 |
7.88e-3 |
59/77 (76.62%) |
CDC42;DOCK1;CAV2;...
|
| ErbB signaling pathway |
-1.85 |
7.10e-3 |
79/85 (92.94%) |
MAPK1;CRKL;JUN;...
|
| Toll-like receptor signaling pathway |
-1.85 |
6.08e-3 |
94/104 (90.38%) |
STAT1;IFNB1;MAPK1;...
|
| Ferroptosis |
-1.85 |
7.10e-3 |
36/41 (87.8%) |
ACSL4;PCBP2;CP;...
|
| Platelet activation |
-1.86 |
5.68e-3 |
106/124 (85.48%) |
ADCY6;GUCY1B1;RAP1B;...
|
| Human cytomegalovirus infection |
-1.89 |
7.10e-3 |
201/225 (89.33%) |
ARHGEF12;GNA12;IFNB1;...
|
| Chronic myeloid leukemia |
-1.90 |
4.73e-3 |
72/76 (94.74%) |
MAPK1;GADD45G;CRKL;...
|
| Other glycan degradation |
-1.91 |
7.10e-3 |
13/18 (72.22%) |
NEU2;HEXA;GLB1;...
|
| FoxO signaling pathway |
-1.97 |
0.00e+0 |
118/131 (90.08%) |
FASLG;S1PR1;FOXO3;...
|
